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United Kingdom.BACKGROUND Bradycardic agents are of interest for the treat-
ment of ischemic heart disease and heart failure, as heart
rate is an important determinant of myocardial oxygen
consumption.
OBJECTIVES The purpose of this study was to investigate the
propensity of hydroxychloroquine (HCQ) to cause bradycardia.
METHODS We assessed the effects of HCQ on (1) cardiac beating
rate in vitro (mice); (2) the “funny” current (If) in isolated guinea
pig sinoatrial node (SAN) myocytes (1, 3, 10 µM); (3) heart rate and
blood pressure in vivo by acute bolus injection (rat, dose range
1–30 mg/kg), (4) blood pressure and ventricular function during
feeding (mouse, 100 mg/kg/d for 2 wk, tail cuff plethysmography,
anesthetized echocardiography).
RESULTS In mouse atria, spontaneous beating rate was signiﬁ-
cantly (Po .05) reduced (by 9% 3% and 15% 2% at 3 and 10
µM HCQ, n ¼ 7). In guinea pig isolated SAN cells, HCQ conferred a
signiﬁcant reduction in spontaneous action potential ﬁring rate
(17%  6%, 1 μM dose) and a dose-dependent reduction in If
(13%  3% at 1 µM; 19%  2% at 3 µM). Effects were also
observed on L-type calcium ion current (ICaL) (12%  4%
reduction) and rapid delayed rectiﬁer potassium current (IKr)D.J.S., D.T., and R.-A.B.B. are joint senior authors. Address reprint
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1547-5271 B 2015 Heart Rhythm Society. Open access under CC BY license.(35%  4%) at 3 µM. Intravenous HCQ decreased heart rate in
anesthetized rats (14.3%  1.1% at 15mg/kg; n ¼ 6) without
signiﬁcantly reducing mean arterial blood pressure. In vivo
feeding studies in mice showed no signiﬁcant change in systolic
blood pressure nor left ventricular function.
CONCLUSIONS We have shown that HCQ acts as a bradycardic
agent in SAN cells, in atrial preparations, and in vivo. HCQ slows the
rate of spontaneous action potential ﬁring in the SAN through
multichannel inhibition, including that of If.
KEYWORDS Hydroxychloroquine; Electrophysiology; Heart failure;
Arrhythmia; Pacemaker; Heart rate; Ion channels; Funny current; If
ABBREVIATIONS ANOVA ¼ analysis of variance; AP ¼ action
potential; HCQ ¼ hydroxychloroquine; HR ¼ heart rate; ICaL ¼
L-type calcium ion current; If ¼ funny current; IKr ¼ rapid delayed
rectiﬁer potassium current; LV¼ left ventricle; PSS¼ physiological
saline solution; SAN ¼ sinoatrial node; SBA ¼ speciﬁc bradycardic
agent; SDD¼ spontaneous diastolic depolarization; V50¼ voltage
of half-activation
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Laurent et al1 described heart rate (HR) as one of the major
determinants of myocardial oxygen consumption. Resting HR is
an important predictor of cardiac mortality2 and has emerged asa therapeutic target. Accordingly, agents that reduce HRwithout
affecting ventricular contractility are of major clinical interest for
the treatment of ischemic heart disease and heart failure.3 HR
reduction can be achieved with β-adrenoceptor antagonists or
rate-limiting calcium channel blockers; however, these agents
may exert concomitant negative inotropic and hypotensive
effects,4 potentially exacerbating myocardial ischemia.
In 1987, Kobinger and Lillie5 described a novel class of
substances known as speciﬁc bradycardic agents (SBAs), whichhttp://dx.doi.org/10.1016/j.hrthm.2015.05.027
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hemodynamic effects. SBAs have been shown to reduce cardiac
oxygen demand by increasing the diastolic period, which
induces an elevation of subendocardial blood ﬂow.6 The only
known SBA on themarket, ivabradine (S16257), is an agent that
blocks the “funny” current (If) and that acts to slow sinus node
action potential (AP) ﬁring directly in pacemaking cells.7
Interestingly, early work in the late 1950s8 explored the
possibility of using chloroquine or hydroxychloroquine
(HCQ) in the treatment of atrial ﬁbrillation (without much
understanding of the mode of action), with both drugs
demonstrating possible efﬁcacy (although without placebo-
group comparison). Since then, there have been case reports
of a potential bradycardic action of hydroxychloroquine
(HCQ),3,9,10 which have led us to investigate whether this
effect can be observed in cardiac preparations. HCQ was
synthesized in 1950 by Surrey and Hammer.11 Dennis et al12
showed HCQ to be an immunomodulating agent. It is now
widely prescribed for its antimalarial and antirheumatic
effects.13 Here we describe novel SAN-inhibiting properties
of HCQ in isolated cardiac preparations and in vivo anes-
thetized animals. We also investigated the safety of HCQ by
in vivo oral feeding on blood pressure and cardiac contrac-
tility. The effects of HCQ are consistent across species, from
single cells to multicellular preparations. Taken together, our
results support the hypothesis that HCQ may be a viable,
low-cost pharmacologic agent to reduce HR.
Methods
Animal experiments are described in accordance with
Animal Research: Reporting of In Vivo Experiments
(ARRIVE) guidelines14 and conform to the Animals (Sci-
entiﬁc Procedures) Act 1986 (UK).15 Procedures were
performed under British Home Ofﬁce license PPL 30/3080.
Isolated cardiac preparations
An expanded Materials and methods section is available in
the Supplementary Material online.
Mouse atrial preparations
Hearts were rapidly excised from male CD-1 mice (7–9 wk
old) and washed in warm, oxygenated physiological saline
solution (PSS). The preparation was hung in a 371C organ
bath ﬁlled with PSS. Beating rate was calculated in real-time
from the upstroke of the tension signal. Drugs were added
cumulatively, directly to the organ bath.
Guinea pig SAN cell isolation
Hearts were excised from male guinea pigs (350– 500 g) and
rinsed in modiﬁed Tyrode solution. SAN myocytes were
then isolated enzymatically.
Single-cell electrophysiology
Perforated patch clamp recordings were carried out, using
amphotericin (250 µg/mL) to achieve perforation.AP recordings
APs were recorded from single guinea pig SAN cells under
current clamp conditions.
Voltage clamp recordings
Full current–voltage relations for If and L-type calcium
ion current (ICaL) as well as rapid delayed rectiﬁer potas-
sium current (IKr) measurements were taken at 0 minutes
and 5 minutes of exposure to HCQ. Please refer to the
supplementary material online.
Rat in vivo, invasive hemodynamic studies
HR and arterial blood pressure were measured under general
anesthesia in male Sprague Dawley rats (300–350 g), via
cannulation of the left carotid artery.
Mice in vivo, noninvasive blood pressure by tail cuff
plethysmography and cardiac contractility studies
by echocardiography
Automated noninvasive tail cuff plethysmography (Visitech
2000; Visitech Systems, Apex, NC) was used to determine
systolic blood pressure in response to HCQ in drinking water,
which was compared with that of a control group. Echocar-
diography was performed at the end of the study in both groups.
Statistics
In vitro statistics
For in vitro statistics, data are presented as means plus or
minus standard error (SEM) and analyzed using 1- or 2-way
analysis of variance (ANOVA) and with repeated measures
where appropriate. Post hoc tests used the Dunnett correc-
tion. P valueso .05 were considered statistically signiﬁcant.
In vivo statistics
For in vivo statistics, data are presented as means þ/- SEM
and all data passed a normality test. Within group compar-
ison are made using a 1-way ANOVA, with post hoc analysis
to determine signiﬁcance (Newman–Keuls, Po .05). Where
in vivo data from 2 groups are compared, these data were
analyzed with an unpaired 2-tailed t test.
Results
Bradycardic effects of HCQ on isolated mouse
atrial preparation
The application of cumulative doses of HCQ to spontane-
ously beating mouse atrial preparations revealed a dose-
dependent reduction in beating rate (P o .05) that was
signiﬁcant at a dose of 3 µM (9%  3% slower than control
rate, P o .05) and further enhanced at 10 µM (15%  2%
slower than control rate, Po .05). Figure 1 demonstrates the
beating rate in beats per minute and rate change in relation to
control for all concentrations applied. No rate change was
seen during time-matched control experiments in which the
method was repeated without the addition of HCQ (1.4% 
2.6% decrease from control in 2 h, P4 .05, n ¼ 6). Starting
Figure 1 Dose-dependent effect of hydroxychloroquine on spontaneous beating rate in mouse atrial preparations. A: A bar graph showing the effect of
cumulative doses of hydroxychloroquine (HCQ) on the sinoatrial node (SAN) beating rate in spontaneously beating preparations (361C 11C). HCQ elicited a
reduction in beating rate (Po .05, 1-way analysis of variance ANOVA), which was signiﬁcantly different from that of the control group at 3 μM (9%  3%
reduction from the control rate, Po .05) and was further reduced at 10 μM (15% 2% reduction from the control rate, Po .05). For all concentrations, n¼ 7.
*Signiﬁcant difference from 0 µM. B: A line graph to compare the percentage change in atrial beating rate during cumulative HCQ doses with that in time-
matched controls. There was no signiﬁcant effect of time on beating rate in control preparations (P 4 .05, 2-way ANOVA, n ¼ 6 control and n ¼ 7 HCQ).
*Signiﬁcant difference between drug and time-matched controls by post hoc testing.
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application, were not signiﬁcantly different (P ¼ .72).
To conﬁrm that the effects of HCQ on rate reduction were
likely to arise from the modulation of If without the signiﬁcant
contribution of other mechanisms, we performed a sequential
accumulation protocol similar to those performed by Verrier
et al.16 Near-maximal inhibition of If was achieved using 1 µM
ZD7288 (If inhibitor), followed by cumulative doses of HCQ
(Supplementary Figure 1). Applied alone, 1 µM ZD7288
caused a signiﬁcant fall in spontaneous beating rate (-38% 
5% from that with PSS, Po .05, n ¼ 7). On the background
of this If inhibition, the cumulative additions of 3 (n ¼ 5) and
10 µM (n¼ 6) HCQ did not confer any additional rate change
(0%  2% and 5%  5%, respectively; P ¼ .89).Effects of HCQ on spontaneous ﬁring frequency in
isolated guinea pig SAN cells
Historically, mechanistic studies of SAN have focused on the
guinea pig and rabbit as experimental models (in terms of AP
shape and length in comparison with those of humans).7
Therefore, the effect of HCQ on spontaneous frequency was
also tested in isolated SAN myocytes from the guinea pig.
A representative trace to show SAN APs recorded before and
after HCQ exposure is provided in Figure 2A. Consistent
with data collected from multicellular preparations, these
results show that HCQ induced a signiﬁcant reduction in the
rate of spontaneous AP generation. This ﬁnding amounted to
a -17%  6% change in 5 minutes at a dose of 1 µM (P o
.05, n ¼ 6, Figure 2B). In the absence of drug intervention,
cells that were patched but not treated with HCQ exhibited
no signiﬁcant change in rate in 5 minutes (0.9% 2.0%, P¼
.83, n ¼ 8, data not shown). Further analysis of AP recorded
during HCQ experiments revealed that slowing was accom-
panied by a 25% 3% reduction in the slope of spontaneous
diastolic depolarization (P o .05, n ¼ 6, Figure 2C) and
an 11%  3% lengthening in AP duration (Po .05, n ¼ 6,
Figure 2D). AP amplitude, maximal upstroke velocity,and maximum diastolic potential were not signiﬁcantly
altered during a 5-minute, 1-µM HCQ application (see
Supplementary Table 1 for summary values).Effects of HCQ on If, IKr, and ICaL in isolated guinea
pig SAN cells
The striking reduction in the slope of diastolic depolarization
observed in single-cell experiments (Figure 2C) led us to
investigate the effects of HCQ on If as a ﬁrst possible
mechanism by which observed rate-slowing may occur. If
recordings were made, using a voltage clamp, of healthy
guinea pig SAN myocytes from a holding potential of -40
mV to a range of hyperpolarizing voltages, in 10-mV
increments, from -50 to -120 mV.
Figure 3 provides representative traces of If measured
across the full range of voltage steps under control conditions,
after 5 minutes of HCQ superfusion (3 µM), and at 10 minutes
after a return to PSS (Figures 3A, 3B, and 3C respectively).
The superfusion of 3 µM HCQ resulted in a signiﬁcant
reduction in the size of If within 5 minutes, for instance by
20%  4% at the voltage step of -100 mV (n = 4).
The maximal conductance of If was signiﬁcantly reduced by
3 µM HCQ (to 85%  6% of the maximal value recorded in
PSS, n= 4, Figure 3D). This reduction was not accompanied by
an effect on the voltage of half-activation (-81.8  1.7 mV in
the control group, -85.0  2.6 mV in the HCQ group) nor the
slope of activation (10.86  1.85 vs 10.83  2.93) as
determined by the ﬁtting of a Boltzmann sigmoidal function.
As shown by the example provided in Figure 3C and the
conductance curve in Figure 3D, a return to PSS resulted in a
complete recovery of If by 10 minutes (n ¼ 4).
Interestingly, and in contrast to data reported during
exposure to ivabradine,17 the average percentage reduction
exhibited on a step to a potential likely to be encountered dur-
ing physiological pacemaker cell ﬁring (-50 or -60 mV)
was greater than the reduction exhibited at a more extreme
hyperpolarization (-70 mV or beyond). Taking an average of
Figure 2 A: Representative traces to show spontaneous action potentials recorded from the same, isolated sinoatrial node (SAN) myocyte under perforated
patch conditions before and after 1 μM hydroxychloroquine (HCQ) (351C  21C). B: HCQ reduces the action potential ﬁring rate in isolated guinea pig SAN
cells. A summary bar graph to show absolute action potential ﬁring rate in Hertz before and during 1 μMHCQ application (n¼ 6). The action potential ﬁring rate
was signiﬁcantly slowed by superfusion of 1 μM HCQ (P o .05, 1-way analysis of variance), with slowing signiﬁcant by 3 min of exposure (10%  3%
reduction, Po .05) and further reduced at 5 min (17% 6% reduction, Po .05). *Signiﬁcant difference from control. The same 6 cells were further analyzed to
determine action potential characteristics: 1 μM HCQ C: signiﬁcantly reduced the rate of spontaneous diastolic depolarization (SDD) and D: signiﬁcantly
lengthened the action potential duration. *Signiﬁcant effect by 1-way analysis of variance with the Dunnett correction.
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polarization steps, the reduction in raw current was 47% 9%
(n¼ 8, where n is change at 1 voltage step in 1 cell), whereas at
potentials from -70 to -120 mV, the reduction in raw current
was 24%  3% (n ¼ 24). The “physiological” group exp-
erienced a signiﬁcantly higher percentage reduction (P o .05
by Student t test).
In multicellular preparations, the effect of HCQ on
spontaneous beating rate was observed to be dose-
dependent. If the observed inhibition of If is responsible for
these rate changes, it should follow that the effect of HCQ on
this current is also dose-dependent. We investigated the effect
of HCQ on If across 3 doses: 1, 3, and 10 µMusing repeated 2-
second steps to -100 mV delivered at 20-second intervals.
Representative traces are shown in Figure 3E. At all doses
tested, we observed a signiﬁcant reduction in the amplitude of
If measured by these step hyperpolarizations. This inhibition
was dose-dependent (P o .05, 1-way ANOVA). The
maximum effect was 13%  3% at a dose of 1 µM (n ¼ 7),
19% 2% at 3 µM, (n¼ 5), and 32% 7% at 10 µM (n¼ 4).
These data are summarized in Figure 3F.
We also performed a simulation using the mathematical SAN
electrophysiology model of Dokos et al18 to reproduce the
physiological and pharmacologic HR modulation (details and a
link to open source code in SupplementaryMaterial). This results
in a 9.7% prolongation in AP duration at 50% of repolarization atfull block, with a reduction in AP ﬁring rate from 2.6 to 2.3 Hz
(from 156 to 138 beats per minute), as shown in Supplementary
Figure 2. The changes in ﬁring rate (Figures 2A and 2B) and AP
duration (Figure 2D) are reproduced relatively well by the
simulation of a block of If solely.
We studied the effects of 3 µM of HCQ on IKr and ICaL and
observed a signiﬁcant effect on these currents. A dose of 3 µM
HCQ caused a signiﬁcant reduction in the amplitude of
potassium tail currents ( P o .05, effect of “drug,” 2-way
ANOVA, n ¼ 5, Figure 3G) with a 35%  4% reduction in
maximal IKr (average of current at 80-, 90-, and 100-ms step
durations). Representative traces to show potassium tail
currents before and after 5 minutes of exposure to 3 µM
HCQ are presented in Supplementary Figures 3A and 3B. The
effects of 3µM HCQ on IKr and estimated IKs are presented in
Supplementary Figures 3C and 3D. ICaL current density was
also inhibited by 3 µM HCQ over 5 minutes (Po .05, effect
of ‘drug’, 2-way ANOVA, n ¼ 6, Figure 3H) with the
maximal current (step to 0 mV) reduced by 12%  4%
(Supplementary Figure 3E shows representative traces).Chronotropic effects of hydroxychloroquine on
anesthetized adult rats
As can be seen in the raw data trace in Figure 4, intravenous
administration of HCQ produces a transient drop in HR and
Figure 3 Representative traces showing current–voltage relations under A: control conditions (in physiological saline solution [PSS]), B: after a 5-min
exposure to 3 µM hydroxychloroquine, and C: after 10 min of wash-out by return to PSS. D: Conductance curves (n¼ 4 cells) with conductance plotted relative
to maximal activation of If under control conditions (PSS). Maximal conductance was signiﬁcantly reduced over 5 min (to 85%  6% of control), whereas
voltage of half-activation (V50) and slope of conductance were unchanged.E: Representative curves illustrating the effect of hydroxychloroquine at 1 and 10 µM
on voltage steps to -100 mV. Data collected using repeated voltage steps to -100 mV at a rate of 0.05 Hz over 5-min HCQ exposure. F: Change in If at the -100
mV step across 3 concentrations (5-min exposure). Signiﬁcant effect of concentration (Po .05) by analysis of variance (ANOVA), n ¼ 7 for 1 µM, n ¼ 5 for 3
µM, and n ¼ 4 for 10 µM of HCQ. G: Potassium current density under control and 3 µM HCQ conditions (signiﬁcant effect, P o .05, of “drug” by 2-way
ANOVA, n ¼ 5) with reduction in maximal IKr (average of 80-, 90-, and 100-ms step lengths) of 35%  4%. H: ICaL current–voltage relations with current
normalized to maximal current density step show a signiﬁcant effect of 3 µM HCQ on ICaL (Po .05, 2-way ANOVA, n ¼ 6) with reduction in the maximal
current (0-mV step) of 12%  4%.
Heart Rhythm, Vol 12, No 10, October 20152190blood pressure, which is then compensated for over the
subsequent minutes. A signiﬁcant transient reduction in HR
is observed at cumulative doses of 7.5 mg/kg and above
(Figure 4C). At 20 mg/kg and above, HR remains signiﬁ-
cantly below the baseline rate even during the compensatory
period. In contrast, mean arterial pressure is compensated
for at all doses used and the transient drop in pressure is
signiﬁcant only at doses of 20 mg/kg and above (Figure 4D).
The percentage transient change in HR at 15 mg/kg (thehighest dose with no signiﬁcant change in mean arterial
blood pressure) is 14.3%  1.1%.Efﬁcacy studies on blood pressure and contractile
function in adult mice
In view of the transient reduction in blood pressure seen on
intravenous administration of HCQ, we conducted a long-
term feeding study with blood pressure measurements and
Figure 4 Acute in vivo experiments; anesthetized (2% isoﬂurane) adult Sprague Dawley rat (male), heart rate and blood pressure responses (measured directly
via left carotid cannula) to cumulative intravenous doses of A: vehicle and B: hydroxychloroquine via left carotid artery. C: Heart rate responses and D:Mean
arterial pressure responses. *Po .05 control (C) vs transient drop (ANOVA/Bonferroni);þPo .05 control (C) vs equilibrated response (ANOVA/Bonferroni).
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As shown in Figure 5A, administration of HCQ (100 mg/kg)
in the drinking water did not alter blood pressure from the
baseline value in the treatment group (HCQ baseline 109.7 
2.89 mm Hg vs end of study 110.7% 1.91 mm Hg, P ¼ not
signiﬁcant, n¼ 9 per group). All animals were weighed daily to
ascertain whether they were consuming the drug, and no
signiﬁcant weight loss was observed in control or drug groups
(control start/end weight 28.08 0.29 g/31.56 0.63 g, HCQ
start/end weight 27.72 0.36 g/29.99 0.58 g). Transthoracic
echocardiograms of mice treated with HCQ in drinking water in
comparison with those of control mice given vehicle solution
(n¼ 9 per group) revealed no signiﬁcant effect of HCQ on left
ventricle (LV) contractility, as judged by fractional shortening
(HCQ group 39.1%  1.2%, control group 39.1%  2.0%),
ejection fraction (HCQ group 70.3%  1.4%, control group
70.0%  2.5%), and fractional area change in myocardial
cross-sectional area (HCQ group 55.0% 1.5%, control group
54.4%  3.2%); on ventricular end-diastolic volume (HCQ
group 57.1  2.7 µL, control group 56.4 3.1 µL); or on LV
mass (HCQ group 101.7 5.1 mg, control group 100.8 3.9
mg) in comparison with those of control mice given vehicle
solution (Figures 5B–5E).Discussion
Pacemaking is a basic physiological process, inherent to the
cells of the SAN. The basic cellular and molecular processes
underlying pacemaking are a major target of cardiac thera-
pies.19 Pacemaking cells exhibit spontaneous diastolic depola-
rization in phase 4 of the AP, which distinguishes them from the
myocytes of the working muscle. This diastolic depolarizationis what allows the repeated, rhythmic, spontaneous generation
of APs.19 In the late 1970s, a hyperpolarization-activated funny
current was discovered to play a major role in pacemaking
mechanism in the SAN and was named If.
20 Today, the only
approved clinical agent to target this ion channel is ivabradine,
which is prescribed in a narrow therapeutic window.21 The
antiﬁbrillatory effects of cholorquine on different ion channels
has been extensively investigated.22 Here we observe a
reduction in If, IKr, and ICaL. To our knowledge, this is the
ﬁrst preclinical evidence that the widely used agent HCQ acts
on the cardiac If, leading to a reduction in conductance without
concomitant effects on the voltage of half-activation.
This ﬁnding differs from the expected effect of changes in
cyclic adenosine monophosphate, and therefore of autonomic
signaling, which would lead to a shift of the voltage of half-
activation without modulation of the maximal achievable
conductance at the most negative voltage steps.23 Instead, the
effect of HCQ on If conductance curves is similar to experi-
ments measuring If modulation using the speciﬁc If blocker
ivabradine.23 Experiments performed in guinea pig SAN cells
showed that HCQ acts mainly by reducing spontaneous
diastolic depolarization, without a signiﬁcant change in further
AP characteristics. As with all proposed SBAs,5 HCQ will
exert effects on pacemaking mechanisms beyond modulation
of If as dose is increased; the results of our sequential
accumulation protocol with ZD7288 are promising, suggest-
ing that HCQ does not reduce beating rate under conditions in
which complete block of If has already been achieved.
Transient bradycardia was also observed with an in vivo
cumulative dose of HCQ of 7.5 mg/kg and above, initia-
lly without any effect on blood pressure. At high doses
(Z20 mg/kg), the effects on blood pressure become signiﬁcant.
Figure 5 Effects of oral hydroxychloroquine on A: systolic blood pressure by tail cuff plethysmography (n ¼ 9/group, dose 100 mg/kg in drinking water,
28 d). Echocardiography was performed under anesthesia with a 30-MHz linear array transducer. Assessment of C and D: contractile function and left
ventricular end-diastolic chamber size by echocardiography at the end of the feeding study. E: i: Example M-mode parasternal short-axis at midventricular level
in both groups (no signiﬁcant difference), Arrows, End-diastolic dimension (EDd) and end-systolic dimension (ESd) of left ventricle; ii: Example parasternal
short-axis view showing end diastole and end systole in both groups, showing no signiﬁcant effect on ventricular end-diastolic volume, end-systolic volume, or
left ventricular mass in comparison with that of control mice.
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contribution of If to pacemaking and its relative importance
in relation to the “calcium clock,”24 the inhibition or genetic
modulation of If has been shown to slow HR signiﬁcantly
and reproducibly in all the species used in this study.
Published preclinical work that has underpinned the
licensing of ivabradine for human use as an SBA has
included ﬁndings from mouse,25 rat,26 guinea pig,7 and
rabbit,27 among other mammalian species. Whatever the
precise role of If for basic pacemaker function, it has an
important role in the autonomic modulation of HR.28 Ourresults suggest that HCQ at 1–3 µM is targeting multiple
membrane ion channels including If. Simulation studies have
shown that a putative compound that blocks multiple
channels (eg, IKr; ICaL; sodium current, INa) can have better
antiarrhythmic effects than ones that block only IKr.
29 Given
the emergence of cardiovascular disease as a leading cause of
death in low-income countries, drug repositioning of HCQ
for the treatment of arrhythmias and angina pectoris may
represent a novel, cost-effective, and safe means particularly
suited to resource-limited settings. In addition, HCQ could
be a potential therapeutic employed in combination therapies
2193Capel et al Hydroxychloroquine as a Rate-Reducing Agent(eg, with angiotensin-converting enzyme inhibitors, calcium
channel antagonists, beta blockers, and other If blockers).
We observed no signiﬁcant change in mean arterial
pressure with lower doses of HCQ in vivo, despite a
lowering of HR. At ﬁrst sight, this may be inferred to
represent compensatory neurohumoral activation to main-
tain systemic arterial pressure in the face of bradycardia.
Notably in this regard, in preclinical models of selective If
inhibitor, ivabradine reduces HR without perturbing cardiac
output or blood pressure by increasing stroke volume via
prolongation of diastolic ﬁling time and potentially through
effects on the extracellular matrix.30 Long-term ivabradine
treatment in human heart failure with reduced ejection
fraction has been shown to reduce effective arterial ela-
stance and increase stroke volume with no change in
systemic vascular resistance, LV contractility, or cardiac
output, a ﬁnding that is consistent with enhanced ven-
tricular-arterial coupling.31 As a corollary, selective HR
lowering by ivabradine has been shown to reduce levels of
natriuretic peptide, a marker of neurohumoral activation of
the myocardium, in heart failure.32 Interpreted in this light,
the lack of effect of HCQ on mean arterial pressure at low
doses supports the hypothesis that it is acting selectively on
the SAN in this dose range.
At extremely high doses, mean arterial pressure was
observed to be signiﬁcantly reduced, which may reﬂect an
additional vasodilatory or negative inotropic action of
HCQ. To assess the efﬁcacy of the drug, we conducted
noninvasive in vivo feeding studies in mice at a dose of 100
mg/kg (highest oral dose tolerated by the mice without
compromising their oral intake) using tail cuff plethysmog-
raphy over 28 days, during which no signiﬁcant changes in
systolic blood pressure were observed. We were unable to
accurately record HR because of the limitations of this
technique. Echocardiography was performed on a cohort of
these animals (blinded studies) with no signiﬁcant changes
observed in contractile function. It is unlikely that equiv-
alent concentrations causing hypotension from intravenous
administration would ever be reached through oral dosing
of HCQ in patients. Moreover, hypotension is not a noted
side effect of dosing for the current uses of this compound
in humans.Conclusions
We describe novel mechanistic insights relating to the action
of HCQ in cardiac preparations. We observe interesting
inhibitory effects on If, IKr, and ICaL. Cardiac arrhythmia is
not a reported side effect of HCQ, despite its widespread use
in healthy (antimalarial) and diseased (rheumatological)
populations. It is possible that blockade of ICaL could be
countering some of the effect of the hERG channel block.29
The experiments described herein studying the funny current
closely mirror those ﬁrst performed to investigate the effects
of known If blockers (eg, ZD7288, ivabradine), and suggest
that further studies regarding cardiac modulation by HCQ is
warranted.Disclosure
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722–727.CLINICAL PERSPECTIVES
Elevated heart rate (HR) is recognized as a predictor of adverse cardiac outcomes and has emerged as a treatment target in
its own right. Lowering HR and thereby myocardial oxygen demand is a well-established strategy to treat angina. Results
from the recent SHIFT (Systolic heart failure treatment with the If inhibitor) trial evaluating the effect of ivabradine on
cardiovascular outcomes, symptoms, and quality of life in patients with chronic heart failure and systolic dysfunction
conﬁrm the pivotal role of HR in the pathophysiology of heart failure and support the strategy of HR reduction for the
improvement of clinical outcomes.33 Our study identiﬁes HCQ, a well-established agent used in the treatment of malaria
and inﬂammatory disorders since the early 1950s, as having a novel speciﬁc HR-lowering effect. Using electro-
physiological and drug-combination experiments across a number of mammalian species, we identify inhibition of the
cardiac pacemaker’s hyperpolarization-activated current, If, as one of the possible mechanisms underlying this rate
reduction. Although HCQ has a well-studied toxicity proﬁle,34 our ﬁndings highlight the need for the monitoring of HR in
patients on high doses of HCQ and the need for caution with coadministration of bradycardic agents. Given the inexpensive
nature and good tolerability proﬁle of HCQ that has been established over decades of clinical experience, our ﬁndings point
to a potential novel role for this old drug as a cost-effective selective HR slowing agent that may be readily tested and
translatable to resource-limited settings worldwide to treat the global epidemic of cardiovascular disease.
